<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47360/1995-4484-2022-341-346</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-3182</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Маркеры активности болезни Стилла взрослых</article-title><trans-title-group xml:lang="en"><trans-title>Biomarkers for adult-onset Still’s disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7590-742X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мячикова</surname><given-names>В. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Myachikova</surname><given-names>V. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197341, Санкт-Петербург, ул. Аккуратова, 2 </p></bio><bio xml:lang="en"><p>197341, Saint Petersburg, Akkuratova str., 2 </p></bio><email xlink:type="simple">myachikova_vyu@almazovcentre.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1479-6551</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ткаченко</surname><given-names>О. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Tkachenko</surname><given-names>O. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197022, Санкт-Петербург, ул. Льва Толстого, 6–8 </p></bio><bio xml:lang="en"><p>197022, Saint Petersburg, L’va Tolstogo str., 6–8 </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4998-3699</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лапин</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lapin</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197022, Санкт-Петербург, ул. Льва Толстого, 6–8 </p></bio><bio xml:lang="en"><p>197022, Saint Petersburg, L’va Tolstogo str., 6–8 </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8598-0391</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кувардин</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuvardin</surname><given-names>E. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197341, Санкт-Петербург, ул. Аккуратова, 2 </p></bio><bio xml:lang="en"><p>197341, Saint Petersburg, Akkuratova str., 2 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2427-4148</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маслянский</surname><given-names>А. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Maslyanskiy</surname><given-names>A. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197341, Санкт-Петербург, ул. Аккуратова, 2;</p><p>199034, Санкт-Петербург, Университетская набережная, 7–9</p></bio><bio xml:lang="en"><p>197341, Saint Petersburg, Akkuratova str., 2;</p><p>199034, Saint Petersburg, Universitetskaya Embankment, 7–9</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр им. В.А. Алмазова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Almazov National Medical Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Первый Санкт-Петербургский медицинский государственный университет им. акад. И.П. Павлова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pavlov First Saint Petersburg State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр им. В.А. Алмазова» Минздрава России;&#13;
ФГБОУ ВО «Санкт-Петербургский государственный университет»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Almazov National Medical Research Centre;&#13;
Saint Petersburg State University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>09</day><month>07</month><year>2022</year></pub-date><volume>60</volume><issue>3</issue><fpage>341</fpage><lpage>346</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мячикова В.Ю., Ткаченко О.Ю., Лапин С.В., Кувардин Е.С., Маслянский А.Л., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Мячикова В.Ю., Ткаченко О.Ю., Лапин С.В., Кувардин Е.С., Маслянский А.Л.</copyright-holder><copyright-holder xml:lang="en">Myachikova V.Y., Tkachenko O.Y., Lapin S.V., Kuvardin E.S., Maslyanskiy A.L.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/3182">https://rsp.mediar-press.net/rsp/article/view/3182</self-uri><abstract><p>Болезнь Стилла взрослых (БСВ) – редкое полигенное аутовоспалительное заболевание неизвестной этиологии. Серьезной проблемой, стоящей перед специалистами, занимающимися БСВ, является отсутствие оптимального метода оценки ее активности. Традиционно используемые стандартные маркеры воспаления не всегда отражают истинную активность БСВ, в особенности, когда пациент уже получает противовоспалительную терапию. В статье представлены оригинальные данные по исследованию биомаркеров: интерлейкина (ИЛ) 1β, ИЛ-6, ИЛ-18, ферритина, гликозилированного ферритина, сывороточного кальпротектина, прокальцитонина в сравнении с С-реактивным белком, количеством лейкоцитов и нейтрофилов у пациентов с умеренной и высокой активностью БСВ. Оценивалась взаимосвязь воспалительных биомаркеров и системного счета Pouchot для выявления перспективных лабораторных показателей активности заболевания. </p></abstract><trans-abstract xml:lang="en"><p>Adult-onset Still’s disease (AOSD) is a rare complex autoinflammatory disease of unknown etiology. The main problem, practitioners have been facing with when researching AOSD, is the lack of developed approaches to assessing the activity of the disease. Traditionally used standard markers of inflammation do not always reflect the real activity of AOSD, especially when a patient is already receiving anti-inflammatory therapy. The article presents original data on the study of biomarkers: interleukin-1 beta (IL-1b), interleukin-6 (IL-6), interleukin-18 (IL-18), ferritin, glycosylated ferritin, calprotectin, procalcitonin compared with C-reactive protein, leukocyte and neutrophil counts in patients with moderate and high activity of AOSD. The relationship between inflammatory biomarkers and the Pouchot systemic score was evaluated to identify promising laboratory indicators of disease activity. </p></trans-abstract><kwd-group xml:lang="ru"><kwd>болезнь Стилла взрослых</kwd><kwd>интерлейкин 1β</kwd><kwd>интерлейкин 6</kwd><kwd>интерлейкин 18</kwd><kwd>гликозилированный ферритин</kwd><kwd>кальпротектин</kwd><kwd>прокальцитонин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>adult-onset Still’s disease</kwd><kwd>AOSD</kwd><kwd>interleukin-1β</kwd><kwd>interleukin-6</kwd><kwd>interleukin-18</kwd><kwd>glycosylated ferritin</kwd><kwd>calgranulin</kwd><kwd>procalcitonin</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнялось в рамках гранта Министерства науки и высшего образования Российской Федерации (договор № 075-15-2020-901).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nat Rev Rheumatol. 2018;14(10):603-618. doi: 10.1038/s41584-018-0081-x</mixed-citation><mixed-citation xml:lang="en">Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nat Rev Rheumatol. 2018;14(10):603-618. doi: 10.1038/s41584-018-0081-x</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Hung WT, Chen YM, Hung SI, Chen HH, Gung NR, Hsieh CW, et al. CARD8 SNP rs11672725 identified as a potential genetic variant for adult-onset Still’s disease. Life (Basel). 2021;11(5):382. doi: 10.3390/life11050382 3. The portal for rare diseases and orphan drugs. URL: https://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&amp;data_id=5525&amp;Disease_Disease_Search_diseaseGroup=AOSD&amp;Disease_Disease_Search_diseaseType (последнее обновление 2019г)</mixed-citation><mixed-citation xml:lang="en">Hung WT, Chen YM, Hung SI, Chen HH, Gung NR, Hsieh CW, et al. CARD8 SNP rs11672725 identified as a potential genetic variant for adult-onset Still’s disease. Life (Basel). 2021;11(5):382. doi: 10.3390/life11050382 3. The portal for rare diseases and orphan drugs. URL: https://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&amp;data_id=5525&amp;Disease_Disease_Search_diseaseGroup=AOSD&amp;Disease_Disease_Search_diseaseType (последнее обновление 2019г)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Cush JJ, Medsger TA Jr, Christy WC, Herbert DC, Cooperstein LA. Adult-onset Still’s disease. Clinical course and outcome. Arthritis Rheum. 1987;30(2):186-194. doi: 10.1002/art.1780300209</mixed-citation><mixed-citation xml:lang="en">Cush JJ, Medsger TA Jr, Christy WC, Herbert DC, Cooperstein LA. Adult-onset Still’s disease. Clinical course and outcome. Arthritis Rheum. 1987;30(2):186-194. doi: 10.1002/art.1780300209</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19(3):424-430.</mixed-citation><mixed-citation xml:lang="en">Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19(3):424-430.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Pepys MB, Hirschfield GM. C-reactive protein: A critical update. J Clin Invest. 2003;111(12):1805-1812. doi: 10.1172/JCI18921</mixed-citation><mixed-citation xml:lang="en">Pepys MB, Hirschfield GM. C-reactive protein: A critical update. J Clin Invest. 2003;111(12):1805-1812. doi: 10.1172/JCI18921</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Riley LK, Rupert J. Evaluation of patients with leukocytosis. Am Fam Physician. 2015;92(11):1004-1011.</mixed-citation><mixed-citation xml:lang="en">Riley LK, Rupert J. Evaluation of patients with leukocytosis. Am Fam Physician. 2015;92(11):1004-1011.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV. Serum ferritin: Past, present and future. Biochim Biophys Acta. 2010;1800(8):760-769. doi: 10.1016/j.bbagen.2010.03.011</mixed-citation><mixed-citation xml:lang="en">Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV. Serum ferritin: Past, present and future. Biochim Biophys Acta. 2010;1800(8):760-769. doi: 10.1016/j.bbagen.2010.03.011</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Zandman-Goddard G, Shoenfeld Y. Ferritin in autoimmune diseases. Autoimmun Rev. 2007;6(7):457-463. doi: 10.1016/j.autrev.2007.01.016</mixed-citation><mixed-citation xml:lang="en">Zandman-Goddard G, Shoenfeld Y. Ferritin in autoimmune diseases. Autoimmun Rev. 2007;6(7):457-463. doi: 10.1016/j.autrev.2007.01.016</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75(4):644- 651. doi: 10.1136/annrheumdis-2015-208690</mixed-citation><mixed-citation xml:lang="en">Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75(4):644- 651. doi: 10.1136/annrheumdis-2015-208690</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Averill MM, Barnhart S, Becker L, Li X, Heinecke JW, Leboeuf RC, et al. S100A9 differentially modifies phenotypic states of neutrophils, macrophages, and dendritic cells: Implications for atherosclerosis and adipose tissue inflammation. Circulation. 2011;123(11):1216- 1226. doi: 10.1161/CIRCULATIONAHA.110.985523</mixed-citation><mixed-citation xml:lang="en">Averill MM, Barnhart S, Becker L, Li X, Heinecke JW, Leboeuf RC, et al. S100A9 differentially modifies phenotypic states of neutrophils, macrophages, and dendritic cells: Implications for atherosclerosis and adipose tissue inflammation. Circulation. 2011;123(11):1216- 1226. doi: 10.1161/CIRCULATIONAHA.110.985523</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Mariani A, Marsili M, Nozzi M, Faricelli R, Chiarelli F, Breda L. Serum calprotectin: Review of its usefulness and validity in paediatric rheumatic diseases. Clin Exp Rheumatol. 2015;33(1):109-114.</mixed-citation><mixed-citation xml:lang="en">Mariani A, Marsili M, Nozzi M, Faricelli R, Chiarelli F, Breda L. Serum calprotectin: Review of its usefulness and validity in paediatric rheumatic diseases. Clin Exp Rheumatol. 2015;33(1):109-114.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Авдеева АС. Клиническое значение кальпротектина при ревматических заболеваниях. Научно-практическая ревматология. 2018;56(4):494-499. doi: 10.14412/1995-4484-2018-494-499</mixed-citation><mixed-citation xml:lang="en">Avdeeva AS. Clinical significance of calprotectin in rheumatic diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(4):494-499 (In Russ.). doi: 10.14412/1995-4484-2018-494-499</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Colafrancesco S, Priori R, Alessandri C, Perricone C, Pendolino M, Picarelli G, et al. IL-18 serum level in adult onset Still’s disease: A marker of disease activity. Int J Inflam. 2012;2012:156890. doi: 10.1155/2012/156890</mixed-citation><mixed-citation xml:lang="en">Colafrancesco S, Priori R, Alessandri C, Perricone C, Pendolino M, Picarelli G, et al. IL-18 serum level in adult onset Still’s disease: A marker of disease activity. Int J Inflam. 2012;2012:156890. doi: 10.1155/2012/156890</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Мячикова ВЮ, Маслянский АЛ, Ткаченко ОЮ, Первакова МЮ, Кувардин ЕС, Лапин СВ. Сравнительный анализ концентраций провоспалительных цитокинов и гликозилированного ферритина у пациентов с идиопатическим рецидивирующим перикардитом и болезнью Стилла взрослых. Российский кардиологический журнал. 2021;26(11):4715. doi: 10.15829/1560-4071-2021-4715</mixed-citation><mixed-citation xml:lang="en">Myachikova VYu, Maslyansky AL, Tkachenko OYu, Pervakova MYu, Kuvardin ES, Lapin SV. Comparative analysis of the concentrations of proinflammatory cytokines and glycosylated ferritin in patients with idiopathic recurrent pericarditis and adult-onset Still’s disease. Russian Journal of Cardiology. 2021;26(11):4715 (In Russ.). doi: 10.15829/1560-4071-2021-4715</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Лапин СВ, Маслянский АЛ, Лазарева НМ, Васильева ЕЮ, Тотолян АА. Значение количественного определения прокальцитонина для диагностики септических осложнений у больных с аутоиммунными ревматическими заболеваниями. Клиническая лабораторная диагностика. 2013;1:28-33.</mixed-citation><mixed-citation xml:lang="en">Lapin SV, Maslyansky AL, Lazareva NM, Vasilyeva YeYu, Totolyan AA. The value of quantitative analysis of procalcitonine in diagnostics of septic complications in patients with autoimmune rheumatic diseases. Russian Clinical Laboratory Diagnostics. 2013;1:28-33 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Hamade B, Huang DT. Procalcitonin: Where are we now? Crit Care Clin. 2020;36(1):23-40. doi: 10.1016/j.ccc.2019.08.003</mixed-citation><mixed-citation xml:lang="en">Hamade B, Huang DT. Procalcitonin: Where are we now? Crit Care Clin. 2020;36(1):23-40. doi: 10.1016/j.ccc.2019.08.003</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Буханова ДВ, Белов БС, Тарасова ГМ, Дилбарян АГ. Прокальцитониновый тест в ревматологии. Клиницист. 2017;11(2): 16-23. doi: 10.17650/1818-8338-2017-11-2-16-23</mixed-citation><mixed-citation xml:lang="en">Bukhanova DV, Belov BS, Tarasova GM, Dilbaryan AG. Procalcitonin testing in rheumatology. The Clinician. 2017;11(2):16- 23 (In Russ.). doi: 10.17650/1818-8338-2017-11-2-16-23</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">van Riel PL, Renskers L. The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(5 Suppl 101):S40-S44.</mixed-citation><mixed-citation xml:lang="en">van Riel PL, Renskers L. The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(5 Suppl 101):S40-S44.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kedor C, Listing J, Zernicke J, Weiß A, Behrens F, Blank N, et al. Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): Phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Ann Rheum Dis. 2020;79(8):1090-1097. doi: 10.1136/annrheumdis-2020-217155</mixed-citation><mixed-citation xml:lang="en">Kedor C, Listing J, Zernicke J, Weiß A, Behrens F, Blank N, et al. Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): Phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Ann Rheum Dis. 2020;79(8):1090-1097. doi: 10.1136/annrheumdis-2020-217155</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Pouchot J, Sampalis JS, Beaudet F, Carette S, Décary F, Salusinsky-Sternbach M, et al. Adult Still’s disease: Manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore). 1991;70(2):118-136.</mixed-citation><mixed-citation xml:lang="en">Pouchot J, Sampalis JS, Beaudet F, Carette S, Décary F, Salusinsky-Sternbach M, et al. Adult Still’s disease: Manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore). 1991;70(2):118-136.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ruscitti P, Cipriani P, Masedu F, Iacono D, Ciccia F, Liakouli V, et al. Adult-onset Still’s disease: Evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Med. 2016;14(1):194. doi: 10.1186/s12916-016-0738-8</mixed-citation><mixed-citation xml:lang="en">Ruscitti P, Cipriani P, Masedu F, Iacono D, Ciccia F, Liakouli V, et al. Adult-onset Still’s disease: Evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Med. 2016;14(1):194. doi: 10.1186/s12916-016-0738-8</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, Файст Е. Болезнь Стилла взрослых: новые горизонты. Научно-практическая ревматология. 2021;59(6):645- 665. doi: 10.47360/1995-4484-2021-643-663</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, Feist E. Adult Still’s disease: New horizons. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(6):645-665 (In Russ.). doi: 10.47360/1995-4484-2021-643-663</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Потапенко ВГ, Первакова МЮ, Лапин СВ, Титов АК, Суркова ЕА, Петрова НН, и др. Роль фракционного анализа ферритина в диагностике вторичного гемофагоцитарного синдрома. Клиническая лабораторная диагностика. 2018;63(1):21-27. doi: 10.18821/0869-2084-2018-63-1-21-27</mixed-citation><mixed-citation xml:lang="en">Potapenko VG, Pervakova MY, Lapin SV, Titov AK, Surkova EA, Petrova NN, et al. The role of fraction analysis of ferritin in diagnostic of secondary hemophagocyte syndrome. Russian Clinical Laboratory Diagnostics. 2018;63(1):21-27 (In Russ.). doi: 10.18821/0869-2084-2018-63-1-21-27</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">United Nations, Department of Economic and Social Affairs, Population Division. World population ageing 2015 (ST/ESA/ SER.A/390). 2015. 26. Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281(1):8-27. doi: 10.1111/imr.12621</mixed-citation><mixed-citation xml:lang="en">United Nations, Department of Economic and Social Affairs, Population Division. World population ageing 2015 (ST/ESA/ SER.A/390). 2015. 26. Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281(1):8-27. doi: 10.1111/imr.12621</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Priori R, Colafrancesco S, Alessandri C, Minniti A, Perricone C, Iaiani G, et al. Interleukin 18: A biomarker for differential diagnosis between adult-onset Still’s disease and sepsis. J Rheumatol. 2014;41(6):1118-1123. doi: 10.3899/jrheum.130575</mixed-citation><mixed-citation xml:lang="en">Priori R, Colafrancesco S, Alessandri C, Minniti A, Perricone C, Iaiani G, et al. Interleukin 18: A biomarker for differential diagnosis between adult-onset Still’s disease and sepsis. J Rheumatol. 2014;41(6):1118-1123. doi: 10.3899/jrheum.130575</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Rau M, Schiller M, Krienke S, Heyder P, Lorenz H, Blank N. Clinical manifestations but not cytokine profiles differentiate adult-onset Still’s disease and sepsis. J Rheumatol. 2010;37(11):2369-2376. doi: 10.3899/jrheum.100247</mixed-citation><mixed-citation xml:lang="en">Rau M, Schiller M, Krienke S, Heyder P, Lorenz H, Blank N. Clinical manifestations but not cytokine profiles differentiate adult-onset Still’s disease and sepsis. J Rheumatol. 2010;37(11):2369-2376. doi: 10.3899/jrheum.100247</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Scheinberg MA, Chapira E, Fernandes ML, Hubscher O. Interleukin 6: A possible marker of disease activity in adult onset Still’s disease. Clin Exp Rheumatol. 1996;14(6):653-655.</mixed-citation><mixed-citation xml:lang="en">Scheinberg MA, Chapira E, Fernandes ML, Hubscher O. Interleukin 6: A possible marker of disease activity in adult onset Still’s disease. Clin Exp Rheumatol. 1996;14(6):653-655.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang W, Yang T, Zhang H, Xu Y, Yang Q, Liu Q, et al. Biomarker screening and validation for the differentiation of bloodstream infection from adult-onset Still’s disease: A prospective cohort study. Cytokine. 2021;146:155642. doi: 10.1016/j.cyto.2021.155642</mixed-citation><mixed-citation xml:lang="en">Zhang W, Yang T, Zhang H, Xu Y, Yang Q, Liu Q, et al. Biomarker screening and validation for the differentiation of bloodstream infection from adult-onset Still’s disease: A prospective cohort study. Cytokine. 2021;146:155642. doi: 10.1016/j.cyto.2021.155642</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
